Abstract: Tumor biology has advanced significantly over the last century, mainly due to advances in cellular signaling pathways, genomics, and epigenomics. The study of cancer epigenetics, including DNA methylation, histone modifications, and non-coding RNAs, has shed light on regulatory disturbances that change chromatin structure and gene expression, promoting carcinogenesis. Beyond only genetic alterations, these discoveries uncover new pathways and potential treatment targets. The importance of immune cells, stromal connections, and signaling molecules in influencing tumor growth and resistance has also been highlighted by advancements in tumor microenvironment (TME) profiling. For example, the ERK/MEK/Raf pathway, which is frequently activated in HCC and other malignancies, underscores crucial links between growth factors and cell division, promoting oncogenesis across multiple organs. Advancements in targeted therapies, including small molecules and monoclonal antibodies, have introduced novel approaches to inhibit these pathways and improve patient outcomes, though challenges like therapeutic resistance persist. Emerging resistance mechanisms, such as the activation of alternative pathways, underscore the need for combination therapies and next-generation inhibitors. Furthermore, technologies, such as liquid biopsies using circulating tumor DNA (ctDNA) and computational models for personalized treatment, mark significant strides toward overcoming intratumoral heterogeneity and adaptive resistance. This comprehensive examination of tumor biology highlights the intricate interplay of epigenetic, genetic, and microenvironmental factors in cancer progression, underscoring the continued need for integrative research. Future oncological strategies will likely focus on a multidisciplinary approach, combining genomics, epigenetics, immune modulation, and bioinformatics to develop more effective, individualized therapies against cancer's complex and evolving landscape.
Chaudhary et al. (Tue,) studied this question.